CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
Top Cited Papers
- 25 November 2017
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 63, 40-47
- https://doi.org/10.1016/j.ctrv.2017.11.007
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Expression and agonist responsiveness of CXCR3 variants in human T lymphocytesImmunology, 2011
- The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27Nature Immunology, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungsInternational Journal of Cancer, 2009
- Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonismBritish Journal of Cancer, 2009
- Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expressionLaboratory Investigation, 2009
- Exploring the full spectrum of macrophage activationNature Reviews Immunology, 2008
- Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapyBreast Cancer Research and Treatment, 2008
- Development of a novel chemokine-mediated in vivo T cell recruitment assayJournal of Immunological Methods, 2008
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmentThe Journal of Experimental Medicine, 2006